Bionaut Pharmaceuticals Inc.
This article was originally published in Start Up
Executive Summary
Bionaut Pharmaceuticals is pioneering a predictive assay platform for drug discovery and lead optimization using engineered cell lines. The firm has established internal small-molecule discovery programs and partnerships in autoimmune/inflammatory diseases and cancer, and is expanding its assay capabilities into other diseases.
You may also be interested in...
Repurposing the Repurposing Business Model
Two recent examples of the difficulties of drug repurposing: Bionaut's ability to find new indications was not sufficient to get a foot in pharma's door without novelty to create barriers to entry to deter fast followers. Sention couldn't generate data fast enough on its L-amphetamine in improving cognitive impairment to counter amphetamine's bad image. (Its second program, even armed with pharma-vetted, baggage-less NCEs in-licensed from Merck, emerged too late to save the company.)
Understanding How To Develop BTK Inhibitors In MS Is Evolving
Having a reversible BTK inhibitor in the multiple sclerosis armamentarium could be the best way to favorably impact the treatment landscape.